| 149 | 1 | 209 |
| 下载次数 | 被引频次 | 阅读次数 |
本研究旨在建立一种快速、通用、高通量的病灶形成测定法（Focus-forming assay, FFA），用于痘苗病毒（Vaccinia virus, VACV）的研究。首先采用经典噬斑染色法与免疫噬斑法对不同VACV代表性毒株（Western Reserve strain, WR; Tiantan strain, VTT; Modified Ankara strain, MVA）在BHK-21细胞和Vero细胞上的噬斑特性进行评估，通过实验条件（包括显色液、非特异性染色、细胞培养板和病毒培养时间）的优化，提高病灶的可视化质量和测定的准确性。并基于改进优化的FFA法研究了VACV在BHK-21细胞和Vero细胞上的生长曲线，同时对FFA法的重复性进行了评估。研究发现BHK-21细胞对VACV的感染更加敏感，适宜于多种VACV滴度测定。实验条件的优化显著提高了病灶的可视化质量和测定的准确性。应用FFA法发现WR、VTT和MVA毒株在BHK-21细胞上能够有效复制，而MVA在Vero细胞上的复制受限，且FFA法在同一实验内具有良好的重复性，变异系数在0.17%到3.50%之间。改进后的FFA法是一种快速、通用、高通量的方法，适用于痘苗病毒滴度的测定，为痘苗病毒的研究和应用提供了可靠的技术支持。
Abstract：We aimed to establish a rapid, universal, high-throughput focus-forming assay(FFA) for vaccinia virus(VACV) research. Initially, the plaque characteristics of representative VACV strains(Western Reserve strain, WR; Tiantan strain, VTT; Modified Ankara strain, MVA) in BHK-21 cells and Vero cells were evaluated using classical plaque-staining and immunostaining methods. Experimental conditions(choice of substrate, non-specific staining, cell culture plates, and virus incubation time) were optimized to enhance the visibility and accuracy of focal detection. An improved FFA method, based on these optimizations, was used to study the growth curves of VACV in BHK-21 cells and Vero cells. The repeatability of the FFA method was assessed. BHK-21 cells were sensitive to VACV infection and suitable for the titration of various VACV strains.Optimization of experimental conditions improved the quality of focal visualization and accuracy of measurement significantly. The FFA method demonstrated effective replication of WR, VTT, and MVA strains in BHK-21cells, whereas replication of MVA in Vero cells was limited. The FFA method showed good repeatability within the same experiment, with a coefficient of variation ranging from 0.17% to 3.50%. The improved FFA method was a rapid, versatile, and high-throughput approach suitable for VACV titration, and provided reliable technical support for the research and application of VACV.
[1] Travieso T, Li J, Mahesh S, et al. The use of viral vectors in vaccine development[J]. NPJ Vaccines,2022, 7(1):75. DOI:10. 1038/s41541-022-00503-y.
[2] Deng Y, Chuai X, Chen P, et al. Recombinant vaccinia vector-based vaccine(Tiantan)boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques[J]. Vaccine, 2017, 35(25):3347-3353. DOI:10. 1016/j.vaccine. 2017. 04. 059.
[3] Zhang Z, Dong L, Zhao C, et al. Vaccinia virus-based vector against infectious diseases and tumors[J]. Hum Vaccin Immunother, 2021, 17(6):1578-1585. DOI:10. 1080/21645515. 2020. 1840887.
[4] Colby D J, Sarnecki M, Barouch D H, et al. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption[J]. Nat Med, 2020,26(4):498-501. DOI:10. 1038/s41591-020-0774-y.
[5] Wang S V, Schneeweiss S, Franklin J M, et al.Emulation of randomized clinical trials with nonrandomized database analyses:results of 32 clinical trials[J]. Jama, 2023, 329(16):1376-1385. DOI:10. 1001/jama. 2023. 4221.
[6] Park B H, Hwang T, Liu T C, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer:a phase I trial[J].Lancet Oncol, 2008, 9(6):533-542. DOI:10. 1016/s1470-2045(08)70107-4.
[7] Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer[J]. Nat Med, 2013, 19(3):329-336. DOI:10. 1038/nm. 3089.
[8] Hwang T H, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma[J]. Mol Ther, 2011, 19(10):1913-1922. DOI:10. 1038/mt. 2011. 132.
[9] Ye M, Keicher M, Gentschev I, et al. Efficient selection of Recombinant Fluorescent Vaccinia Virus Strains and Rapid Virus Titer Determination by Using a Multi-Well Plate Imaging System[J]. Biomedicines,2021, 9(8):1032. DOI:10. 3390/biomedicines9081032.
[10]Case J B, Bailey A L, Kim A S, et al. Growth,detection, quantification, and inactivation of SARS-CoV-2[J]. Virology, 2020, 548:39-48. DOI:10. 1016/j.virol. 2020. 05. 015.
[11]Bailly B, Richard C A, Sharma G, et al. Targeting human respiratory syncytial virus transcription antitermination factor M2-1 to inhibit in vivo viral replication[J]. Scientific Reports, 2016, 6(1):25806. DOI:10. 1038/srep25806.
[12]Cruz D J M, Shin H-J. Application of a focus formation assay for detection and titration of porcine epidemic diarrhea virus[J]. J Virol Methods, 2007, 145(1):56-61. DOI:10. 7554/eLife. 81869.
[13]Waris G, Kang W, Shin E-C. Colorimetric FocusForming Assay with Automated Focus Counting by Image Analysis for Quantification of Infectious Hepatitis C Virions[J/OL]. PLoS ONE, 2012, 7(8):e43960.DOI:10. 1371/journal. pone. 0043960.
[14]Keiser P T, Anantpadma M, Staples H, et al.Automation of Infectious Focus Assay for Determination of Filovirus Titers and Direct Comparison to Plaque and TCID50 Assays[J]. Microorganisms, 2021, 9(1):156. DOI:10. 3390/microorganisms9010156.
[15]Elahi S M, Nazemi-Moghaddam N, Gadoury C, et al.A rapid Focus-Forming Assay for quantification of infectious adenoviral vectors[J]. J Virol Methods,2021, 297:114267.DOI:10. 1016/j.jviromet. 2021. 114267.
[16]Ye C, Wang D, Liu H, et al. An Improved EnzymeLinked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection[J]. Front Pharmacol, 2019, 10:1203. DOI:10. 3389/fphar. 2019. 01203.
[17]Stone E T, Hirsch A J, Smith J L, et al. Titration and neutralizing antibody quantification by focus forming assay for Powassan virus[J]. STAR Protocols, 2022, 3(3):101473. DOI:10. 1016/j. xpro. 2022. 101473.DOI:10. 1016/j. xpro. 2022. 101473.
[18]Earl P L, Cooper N, Wyatt L S, et al. Preparation of cell cultures and vaccinia virus stocks[J]. Curr Protoc Mol Biol, 2001, Chapter 16:Unit16. 16. DOI:10. 1002/0471140864. ps0512s13.
[19]Wiebe M S, Peng C, Wyatt L S, et al. Zinc-finger antiviral protein(ZAP)is a restriction factor for replication of modified vaccinia virus Ankara(MVA)in human cells[J/OL]. PLoS Pathogens, 2020, 16(8):e1008845. DOI:10. 1371/journal. ppat. 1008845.
[20]Liu R, Americo J L, Cotter C A, et al. MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease[J]. bioRxiv, 2021,2020. 12. 30. 424878.DOI:10. 1101/2020. 12. 30. 424878.
[21]Le?o T L, Louren?o K L, de Oliveira Queiroz C, et al.Vaccinia virus induces endoplasmic reticulum stress and activates unfolded protein responses through the ATF6αtranscription factor[J]. Virol J, 2023, 20(1):145.DOI:10. 1186/s12985-023-02122-y.
[22]Kubinski M, Beicht J, Zdora I, et al. A recombinant Modified Vaccinia virus Ankara expressing prME of tickborne encephalitis virus affords mice full protection against TBEV infection[J]. Front Immunol, 2023, 14:1182963. DOI:10. 3389/fimmu. 2023. 1182963.
[23]Ramírez J C, Gherardi M M, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice:virus fate and activation of B-and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine[J]. J Virol,2000, 74(2):923-933. DOI:10. 1128/jvi. 74. 2. 923-933. 2000.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004508
中图分类号:R373
引用信息:
[1]楚巧鸿,冯霞,李佳等.检测痘苗病毒体外感染的病灶形成方法的优化与应用[J].病毒学报,2024,40(03):492-499.DOI:10.13242/j.cnki.bingduxuebao.004508.
基金信息:
国家重点研发计划（项目号：2023YFD1800405）,题目：抗猴痘药物筛选与阻断技术研究;国家重点研发计划（项目号：2022YFC2303401）,题目：潜在高危新病毒风险识别的新技术体系研究~~